Amneal Pharmaceuticals, Inc. AMRX AvKARE — Cost of goods sold

Other segment segments

Similar metrics at other companies

GEHCAVS — Cost of Sales

$662M+10.7%

ZBRAAVA — Cost of sales:

$322M+4.5%

VFCActive — Cost of goods sold

$253.23M-2.3%

MIRMCost of Sales

$28.81M+25.1%

UTHRAdcirca — Cost of Sales

$1M-61.5%

PTCTCost Of Goods And Service Excluding Amortization Of Intangible Assets

$28.03M+118%

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s avkare — cost of goods sold?

Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — cost of goods sold of $126.94M in Q1 2026.

How has Amneal Pharmaceuticals, Inc.'s avkare — cost of goods sold changed year-over-year?

Amneal Pharmaceuticals, Inc.'s avkare — cost of goods sold decreased by 11.7% year-over-year, from $143.81M to $126.94M.

What is the long-term trend for Amneal Pharmaceuticals, Inc.'s avkare — cost of goods sold?

Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s avkare — cost of goods sold has grown at a 20.6% compound annual growth rate (CAGR), from $282.87M to $597.94M.

What does avkare — cost of goods sold mean?

Includes the direct costs attributable to the production and procurement of pharmaceuticals sold by the AvKARE segment, such as raw materials, manufacturing labor, and distribution logistics. Monitoring this metric is essential for evaluating the segment's production efficiency and direct cost management.